| [1] |
Oparil S, Acelajado MC, Bakris GL, et al. Hypertension [J]. Nat Rev Dis Primers, 2018, 4: 18014.
|
| [2] |
Wang J, Zhang L, Wang F, et al. 中国高血压发病率、知晓率、治疗率和控制率的全国性调查结果[J]. 中华高血压杂志，2015, 23(3): 298.
|
| [3] |
Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives [J]. Lancet, 2013, 382(9888): 260-272.
|
| [4] |
Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD [J]. Adv Chronic Kidney Dis, 2015, 22(2): 88-95.
|
| [5] |
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines [J]. Hypertension, 2018, 71(6): 1269-1324.
|
| [6] |
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension [J]. Eur Heart J, 2018, 39(33): 3021-3104.
|
| [7] |
Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019) [J]. Hypertens Res, 2019, 42(9): 1235-1481.
|
| [8] |
Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines [J]. Hypertension, 2020, 38(6): 982-1004.
|
| [9] |
中国高血压防治指南修订委员会，高血压联盟(中国)，中华医学会心血管病学分会，等. 中国高血压防治指南(2018年修订版) [J]. 中国心血管杂志，2019, 24(1): 24-56.
|
| [10] |
Kramer HJ, Townsend RR, Griffin K, et al. KDOQI US commentary on the 2017 ACC/AHA hypertension guideline [J]. Am J Kidney Dis, 2019, 73(4): 437-458.
|
| [11] |
Zheng Y, Tang L, Zhang W, et al. Applying the new intensive blood pressure categories to a nondialysis chronic kidney disease population: the prevalence, awareness and treatment rates in chronic kidney disease patients with hypertension in China survey [J]. Nephrol Dial Transplant, 2020, 35(1): 155-161.
|
| [12] |
Zheng Y, Cai GY, Chen XM, et al. Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients [J]. Chin Med J (Engl), 2013, 126(12): 2276-2280.
|
| [13] |
McEvoy JW, Daya N, Rahman F, et al. Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes [J]. JAMA, 2020, 323(4): 329-338.
|
| [14] |
Bundy JD, Mills KT, He J. Comparison of the 2017 ACC/AHA hypertension guideline with earlier guidelines on estimated reductions in cardiovascular disease [J]. Curr Hypertens Rep, 2019, 21(10): 76.
|
| [15] |
Xie Y, Gao J, Guo R, et al. Stage 1 hypertension defined by the 2017 ACC/AHA guideline predicts future cardiovascular events in elderly Chinese individuals [J]. J Clin Hypertens (Greenwich), 2019, 21(11): 1637-1644.
|
| [16] |
Yang WY, Melgarejo JD, Thijs L, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes [J]. JAMA, 2019, 322(5): 409-420.
|
| [17] |
Bangash F, Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis [J]. Clin J Am Soc Nephrol, 2009, 4(3): 656-664.
|
| [18] |
Ku E, Hsu RK, Tuot DS, et al. Magnitude of the difference between clinic and ambulatory blood pressures and risk of adverse outcomes in patients with chronic kidney disease [J]. J Am Heart Assoc, 2019, 8(9): e011013.
|
| [19] |
Drawz PE, Alper AB, Anderson AH, et al. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage [J]. Clin J Am Soc Nephrol, 2016, 11(4): 642-652.
|
| [20] |
Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood pressure measurements and mortality [J]. N Engl J Med, 2018, 378(16): 1509-1520.
|
| [21] |
Wang C, Zhang J, Li Y, et al. Masked hypertension, rather than white-coat hypertension, has a prognostic role in patients with non-dialysis chronic kidney disease [J]. Int J Cardiol, 2017, 230: 33-39.
|
| [22] |
Rossignol P, Massy ZA, Azizi M, et al. The double challenge of resistant hypertension and chronic kidney disease [J]. Lancet, 2015, 386(10003): 1588-1598.
|
| [23] |
Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study [J]. Am J Kidney Dis, 2010, 55(3): 441-451.
|
| [24] |
Liu B, Wang Q, Wang Y, et al. Utilization of antihypertensive drugs among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE) [J]. J Clin Hypertens (Greenwich), 2020, 22(1): 57-64.
|
| [25] |
Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis [J]. JAMA Cardiol, 2017, 2(7): 775-781.
|
| [26] |
Modi GK, Agarwal R. What are optimal blood pressure targets for patients with hypertension and chronic kidney disease? [J]. Curr Cardiol Rep, 2015, 17(11): 101.
|
| [27] |
Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood pressure control [J]. N Engl J Med, 2015, 373(22): 2103-2116.
|
| [28] |
Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population [J]. J Am Coll Cardiol, 2014, 64(6): 588-597.
|
| [29] |
Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review [J]. JAMA, 2019, 322(13): 1294-1304.
|
| [30] |
Minutolo R, De Nicola L, Gallo C, et al. Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics [J]. J Nephrol, 2019, 32(3): 429-435.
|
| [31] |
Appel LJ, Wright JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease [J]. N Engl J Med, 2010, 363(10): 918-929.
|
| [32] |
Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier [J]. Ann Intern Med, 2011, 154(8): 541-548.
|
| [33] |
Agostinis-Sobrinho C, Gómez-Martínez S, Nova E, et al. Lifestyle patterns and endocrine, metabolic, and immunological biomarkers in European adolescents: the HELENA study [J]. Pediatr Diabetes, 2019, 20(1): 23-31.
|
| [34] |
Li Y, Schoufour J, Wang DD, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study [J]. BMJ, 2020, 368: 16669.
|
| [35] |
Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes [J]. Kidney Int, 2017, 91(3): 683-690.
|
| [36] |
Hannedouche T, Roth H, Krummel T, et al. Multiphasic effects of blood pressure on survival in hemodialysis patients [J]. Kidney Int, 2016, 90(3): 674-684.
|
| [37] |
Ng SYA, Haynes R, Herrington WG. Haemodialysis, blood pressure and risk: at the limit of non-randomized evidence [J]. Nephrol Dial Transplant, 2020, 35(9): 1465-1468.
|
| [38] |
Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation [J]. Am J Kidney Dis, 2004, 43(6): 1071-1081.
|